Company: IMNN
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001641172-25-013088
Chunk: 8

Company: Imunon, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 8
---
 with the Private Placement, pursuant to that certain engagement letter, dated as of May 22, 2025, between the Company and H.C. Wainwright & Co., LLC (the “ Engagement Letter”). In addition, the Company issued to designees of H.C. Wainwright & Co., LLC the Placement Agent Warrants to purchase up to an aggregate of 361,111 shares of Common Stock at an exercise price equal to $0.5625 per share. The Placement Agent Warrants have substantially the same terms as the Common Warrants and will be exercisable upon receipt of Stockholder Approval.

Recent Developments

On March 24, 2025, we issued a press release announcing finalization of our Phase 3 study design for IMNN-001, a treatment for women with newly diagnosed advanced ovarian cancer, and that the U.S. Food and Drug Administration is aligned with the protocol for the Phase 3 pivotal trial, called OVATION 3, of our lead candidate IMNN-001. On May 23, 2025, we issued a press release announcing new positive data from our Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer.

On May 12, 2025, the Company entered into an exchange agreement (the “ Exchange Agreement”) with the holders (the “ Existing Warrant Holders”) of certain warrants of the Company (the “ Existing Warrants”) issued on August 1, 2024, which were exercisable for an aggregate of 5,000,000 shares of Common Stock. Pursuant to the terms of the Exchange Agreement, the Company issued to the Existing Warrant Holders an aggregate of 2,921,000 shares of Common Stock (the “ Warrant Exchange Shares”), on a one-for-one basis, in exchange for shares issuable under the Existing Warrants (the “ Warrant Exchange”), in reliance on an exemption from registration provided by Section 3(a)(9) of the Securities Act. The Warrant Exchange closed on May 13, 2025. The number of Warrant Exchange Shares issued pursuant to the Exchange Agreement represented 19.98% of the shares of Common Stock outstanding as of the date of the Exchange Agreement.

On May 19, 2025, the Company received a letter from the staff (the “ Staff”) of Nasdaq indicating that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing pursuant to Nas